Monashee Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

Monashee Investment Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-85,000	Closed	-$2.59M	–	67
2022 Q2	$2.59M	Buy	+85,000	New	+$2.57M	0.94%	9
2021 Q4	–	Sell	-180,000	Closed	-$2.75M	–	123
2021 Q3	$2.75M	Buy	+180,000	New	+$3.13M	0.51%	45
2021 Q2	–	Sell	-10,365	Closed	-$186K	–	480
2021 Q1	$186K	Buy	+10,365	New	+$176K	0.03%	254
2018 Q3	–	Hold	0	–	–	–	104
2016 Q3	–	Hold	0	–	–	–	80

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Monashee Investment Management's XENE Position: Q3 2022 in Review

Monashee Investment Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2022, closing a stake of 85,000 shares — an estimated $2.59M sold.

Monashee Investment Management first reported a position in XENE in Q1 2021 and held it in 3 quarters. The position peaked at $2.75M in Q3 2021. 154 funds tracked by Wall St. Rank hold XENE as of Q3 2022.

Monashee Investment Management reported no remaining Xenon Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Monashee Investment Management sold 85,000 Xenon Pharmaceuticals shares in Q3 2022, an estimated $2.59M.
Monashee Investment Management first reported a position in Xenon Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Monashee Investment Management's Xenon Pharmaceuticals position peaked at $2.75M in Q3 2021.
154 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2022.

Based on Monashee Investment Management's 13F filing for Q3 2022, filed 1 Nov 2022.